๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› USA
Clinical trial register · United States · industry-sponsored

Industry-sponsored studies with a US investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9110 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:16 UTC
9110
Studies in scope
industry-sponsored, all four open statuses
4947
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 142 Florida 112 Illinois 101 Arizona 74 Georgia 66
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca299 Novartis Pharmaceuticals202 Eli Lilly and Company190 Merck Sharp & Dohme LLC183 AbbVie172 Clear sponsor filter
State
California142 Florida112 Illinois101 Arizona74 Georgia66
All 46 states
Target enrolment
to
172 of 9110 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
AbbVie
Phase 3
110
Arizona, Arkansas, California, Colorado, Florida, Indiana, Massachusetts, Minnesota
2023-12-11
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2023-11-15
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
NCT06107413Unresectable Metastatic Colorectal Cancer
AbbVie
Phase 2
280
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Louisiana
2023-11-12
Recruiting
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
AbbVie
Phase 1
325
California, Colorado, Florida, Illinois, Michigan, Missouri, New York, North Carolina
2023-11-09
Active, closed
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907Ulcerative Colitis
AbbVie
Phase 3
122
Arizona, Arkansas, California, Colorado, Delaware, Georgia, Illinois, Massachusetts
2023-11-06
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
AbbVie
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-10-11
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
AbbVie
Phase 3
90
Arizona, District of Columbia, New York, North Carolina, Ohio, Oregon
2023-10-02
Active, closed
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT05822752Hepatocellular Carcinoma
AbbVie
Phase 2
130
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Massachusetts
2023-09-21
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
AbbVie
Phase 3
1,014
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-25
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
AbbVie
Phase 3
1,328
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2023-06-21
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
AbbVie
Phase 1
135
Arizona, California, Colorado, Illinois, Massachusetts, New Jersey, New York, Ohio
2023-06-09
By invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949Migraine Prophylaxis
AbbVie
Phase 3
650
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-06-05
Recruiting
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394Episodic Migraine
AbbVie
Phase 3
450
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-05-01
Active, closed
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
NCT05512390Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
AbbVie
Phase 1
39
Arizona, Florida, Minnesota, Nebraska, New York, North Carolina, Texas
2023-04-26
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
California, Connecticut, Florida, Indiana, Louisiana, Michigan, New York, North Carolina
2023-04-04
Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632Multiple Myeloma
AbbVie
Phase 1
210
Arizona, Arkansas, Colorado, Delaware, Illinois, Indiana, Louisiana, Maryland
2023-03-21
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa
2023-03-15
Active, closed
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
AbbVie
Phase 1
256
Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Mississippi
2023-01-11
Recruiting
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
NCT05158894Migraine
AbbVie
Observational
1,884
North Carolina
2023-01-10
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
AbbVie
Phase 1
288
Arizona, California, Connecticut, District of Columbia, Illinois, Indiana, Iowa, Michigan
2022-12-05
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839Relapsed/Refractory Multiple Myeloma
AbbVie
Phase 1
283
Arkansas, Florida, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina
2022-10-20
Active, closed
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRฮฑ) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 2
125
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts
2022-09-28
Active, closed
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
NCT05308654Relapsed/Refractory Multiple Myeloma
AbbVie
Phase 1
34
California, Florida, Louisiana, Maryland, Michigan, Minnesota, New York, North Carolina
2022-05-17
By invitation
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
NCT05296447Diabetic Retinopathy, DR
AbbVie
Phase 2
100
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Jersey
2022-04-04
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 2
75
California, Georgia, Iowa, Massachusetts, Michigan, Minnesota, Mississippi, New Jersey
2022-03-28
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana
2022-03-25
By invitation
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
NCT05127954Migraine
AbbVie
Phase 3
1,200
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-01-14
Recruiting
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302Migraine
AbbVie
Phase 3
1,059
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-01-13
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
AbbVie
Phase 3
735
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2022-01-13
Active, closed
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naรฏve to Biologic Therapy
NCT05139602Hidradenitis Suppurativa
AbbVie
Phase 2
210
Arizona, Arkansas, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2021-12-28
By invitation
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
NCT05210803Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie
Phase 2
116
Arizona, California, Georgia, Maryland, Massachusetts, Minnesota, Nevada, New Mexico
2021-12-20
Recruiting
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT05005403Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
AbbVie
Phase 1
694
California, Illinois, Indiana, Kentucky, Michigan, Minnesota, Nebraska, North Carolina
2021-11-01
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
AbbVie
Phase 1
520
California, Colorado, Connecticut, Illinois, Indiana, Louisiana, Michigan, New York
2021-10-13
By invitation
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT04880876Irritable Bowel Syndrome
AbbVie
Phase 3
124
California, Florida, Georgia, Oklahoma, Pennsylvania
2021-08-13
Recruiting
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
NCT04846959Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
AbbVie
Observational
818
North Carolina
2021-07-30
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
NCT04862286Psoriasis
AbbVie
Phase 3
132
Alabama, California, Florida, Illinois, Nevada, Ohio, South Carolina, West Virginia
2021-07-24
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
NCT04777357Depression, Bipolar I Disorder
AbbVie
Phase 3
380
Arkansas, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2021-04-28
Active, closed
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
NCT04721015Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 1
81
Massachusetts, Missouri, North Carolina, Rhode Island, Texas, Virginia
2021-02-23
Active, closed
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
AbbVie
Phase 2/3
671
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2020-12-29
Active, closed
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
AbbVie
Phase 2
139
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Jersey
2020-11-20
Active, closed
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248Open-angle Glaucoma, Ocular Hypertension
AbbVie
Phase 1/2
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Massachusetts
2020-11-16
Active, closed
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
NCT04454658Myelofibrosis (MF)
AbbVie
Phase 1
21
California, New Hampshire, New York, Ohio, Oklahoma, Oregon, Texas, Washington
2020-11-11
Active, closed
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611Crohn's Disease (CD)
AbbVie
Phase 3
527
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana
2020-09-30
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
AbbVie
Phase 3
531
California, Colorado, Connecticut, Delaware, Florida, Idaho, Illinois, Indiana
2020-09-10
Active, closed
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04468984Myelofibrosis (MF)
AbbVie
Phase 3
330
Arizona, Arkansas, California, Colorado, Georgia, Illinois, Indiana, Louisiana
2020-08-31
Active, closed
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT04514653Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie
Phase 2
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Mexico
2020-08-25
Active, closed
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
NCT04333576Endometriosis
AbbVie
Phase 3
800
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2020-08-10
Active, closed
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
NCT04041050Myeloproliferative Neoplasm
AbbVie
Phase 1
85
California, Illinois, Kentucky, Michigan, Nebraska, North Carolina, Ohio, Pennsylvania
2019-11-08
Active, closed
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
NCT04086264Acute Myeloid Leukemia
AbbVie
Phase 1/2
218
California, Florida, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2019-11-06
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
AbbVie
Phase 3
165
Arizona, California, Illinois, Massachusetts, Michigan, New Hampshire, Washington
2019-09-06
Active, closed
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
NCT03725007Juvenile Idiopathic Arthritis (JIA)
AbbVie
Phase 1
124
Illinois, Kentucky, Massachusetts, Ohio, Oregon, Pennsylvania, Washington
2019-06-24
Active, closed
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
NCT03933735Multiple Myeloma
AbbVie
Phase 1/2
220
California, Louisiana, Minnesota, Missouri, New York, North Carolina, Wisconsin
2019-06-24
By invitation
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
AbbVie
Phase 2
865
Arizona, California, Maryland, Massachusetts, Nevada, Pennsylvania, Tennessee, Texas
2019-05-31
Active, closed
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03893955Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
AbbVie
Phase 1
150
Arkansas, California, Connecticut, Florida, Indiana, Missouri, North Carolina, Pennsylvania
2019-05-21
Active, closed
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308Psoriatic Arthritis
AbbVie
Phase 3
964
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2019-03-25
Active, closed
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03821935Advanced Solid Tumors Cancer
AbbVie
Phase 1
364
Arkansas, California, Connecticut, Florida, Indiana, Michigan, Missouri, Montana
2019-02-21
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
AbbVie
Phase 3
265
Arizona, California, Colorado, Florida, Kentucky, Maryland, Massachusetts, Michigan
2018-10-22
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
Alabama, Arizona, Arkansas, California, Colorado, Florida, Hawaii, Illinois
2018-10-10
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
AbbVie
Phase 3
1,242
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2018-08-28
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
AbbVie
Phase 3
1,533
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2018-08-09
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
AbbVie
Phase 3
1,336
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2018-04-09
Active, closed
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
NCT03314181Multiple Myeloma
AbbVie
Phase 2
156
Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey, New York, North Carolina
2018-04-02
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
AbbVie
Phase 3
747
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2018-03-21
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
AbbVie
Phase 1/2
179
Alabama, Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina
2018-01-02
Active, closed
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
NCT02988960Advanced Solid Tumors Cancer
AbbVie
Phase 1
163
California, Illinois, Massachusetts, North Carolina, Tennessee, Texas, Virginia
2017-02-22
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naรฏve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
AbbVie
Phase 3
443
California, Georgia, Illinois, Indiana, Kansas, Kentucky, Maine, Maryland
2017-02-02
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
AbbVie
Phase 3
950
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2017-01-31
Active, closed
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
NCT02899052Multiple Myeloma
AbbVie
Phase 2
120
Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, Kentucky, Maine
2017-01-19
Active, closed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159Rheumatoid Arthritis
AbbVie
Phase 3
1,629
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2015-12-01
Active, closed
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362Crohn's Disease
AbbVie
Observational
1,446
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana
2014-08-28
Active, closed
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
NCT02099058Advanced Solid Tumors Cancer
AbbVie
Phase 1
237
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2014-01-15
Active, closed
A Long-Term Registry of Humiraยฎ (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561Ulcerative Colitis (UC)
AbbVie
Observational
8,250
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2013-04-29
Rows per page Showing 101–172 of 172
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-usa?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.